Gu Zander, Gasperoni Francesca, Paige Ellie, Sweeting Michael, Usher-Smith Juliet, Poppe Katrina, Stevens David, Arnold Matthew, Di Angelantonio Emanuele, Wood Angela M, Barrett Jessica K
MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.
Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
BMJ Public Health. 2025 Mar 28;3(1):e001241. doi: 10.1136/bmjph-2024-001241. eCollection 2025 Jan.
The recommended assessment intervals for primary prevention of cardiovascular disease (CVD) differ in major international guidelines. We aimed to provide empirical evidence on the optimal frequency of CVD risk assessment to inform future guidelines.
We estimated the expected time to cross the 10-year CVD risk treatment threshold of 10% using extended two-stage landmarking for more than 2 million people using UK primary care electronic health records between April 2004 and May 2019 from the Clinical Practice Research Datalink GOLD Database (CPRD GOLD), which was linked to hospital admissions data from the Hospital Episodes Statistics (HES) dataset and national mortality records from the Office for National Statistics (ONS). We grouped people based on their sex, initial risk level and age, and computed various percentiles of the expected crossing times per group. Based on the percentiles, optimal assessment intervals were identified and their performance was evaluated comparing to the current recommended intervals in the UK.
Our results showed that the expected crossing times for people with lower initial risk were much longer than those with higher initial risk. Within each initial risk group, expected time to crossing the risk treatment thresholds was shorter in people aged ≥65 years. Based on the median expected crossing times, our recommended intervals for women with initial 10-year risk of 7.5%-10%, 5%-7.5%, 2.5%-5% or<2.5% are 3 (1 if ≥65 years old), 7 (4), 10 (6) and 10 (10) years, respectively; intervals for men are 2 (1), 5 (5), 9 (9) and 10 (10) years. These intervals outperformed the 5-yearly risk reassessment for all individuals currently recommended in the UK.
Our evidence suggests that CVD risk assessment intervals for primary prevention should be stratified by sex, initial risk level and age. For the UK population, our method found risk assessment intervals that reduce the number of assessments required while shortening the waiting time to the next assessment for those most in need.
主要国际指南中关于心血管疾病(CVD)一级预防的推荐评估间隔有所不同。我们旨在提供关于CVD风险评估最佳频率的实证证据,以为未来指南提供参考。
我们使用扩展两阶段地标法,利用2004年4月至2019年5月期间英国基层医疗电子健康记录,对来自临床实践研究数据链黄金数据库(CPRD GOLD)的200多万人进行分析,估计达到10%的10年CVD风险治疗阈值所需的预期时间,该数据库与医院事件统计(HES)数据集的医院入院数据以及国家统计局(ONS)的国家死亡率记录相关联。我们根据性别、初始风险水平和年龄对人群进行分组,并计算每组预期达到阈值时间的不同百分位数。基于这些百分位数,确定最佳评估间隔,并将其性能与英国当前推荐的间隔进行比较。
我们的结果表明,初始风险较低者达到阈值的预期时间远长于初始风险较高者。在每个初始风险组中,年龄≥65岁者达到风险治疗阈值的预期时间较短。根据预期达到阈值时间的中位数,我们对初始10年风险为7.5%-10%、5%-7.5%、2.5%-5%或<2.5%的女性推荐的间隔分别为3年(≥65岁为1年)、7年(4年)、10年(6年)和10年(10年);男性的间隔分别为2年(1年)、5年(5年)、9年(9年)和10年(10年)。这些间隔优于英国目前对所有个体推荐的每5年进行一次风险重新评估。
我们的证据表明,CVD一级预防的风险评估间隔应按性别、初始风险水平和年龄进行分层。对于英国人群,我们的方法找到了风险评估间隔,既能减少所需评估次数,又能缩短最需要者等待下一次评估的时间。